Sex Differences in the Management and Outcomes of Heart Failure with Preserved Ejection Fraction in Patients Presenting to the Emergency Department with Acute Heart Failure [PDF]
, 2015 Background Heart failure (HF) with preserved ejection fraction (HFpEF) is more common in women than in men; data characterizing sex differences in the management and outcomes of HFpEF patients presenting to the emergency department (ED) are limited.
DeVore, Adam D. +8 more
core +1 more source
Reframing the role of glucagon‐like peptide 1 receptor agonists in cardiovascular medicine
ESC Heart Failure, Volume 12, Issue 2, Page 923-926, April 2025.
Riccardo M. Inciardi +3 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1132-1140, April 2025.Abstract The main purpose of this project was to capture experts' opinion on hyperkalaemia management and form best practice recommendations for cardiorenal patients in Greece. A steering committee of nephrologists and cardiologists developed 37 statements. An online questionnaire completed by 32 experts in cardiorenal management in Greece.
Christina Chrysohoou +3 more
wiley +1 more source
A mouse model of heart failure with preserved ejection fraction due to chronic infusion of a low subpressor dose of angiotensin II [PDF]
, 2015 Heart failure (HF) with preserved ejection fraction (HFpEF) is a clinical syndrome of HF symptoms associated with impaired diastolic function. Although it represents ∼50% of patients with HF, the mechanisms of disease are poorly understood, and therapies
Abbate, Antonio +10 more
core +1 more source
Anticoagulation in patients with atrial fibrillation and heart failure: Insights from the NCDR PINNACLE-AF registry. [PDF]
, 2019 BackgroundIn non-valvular atrial fibrillation (NVAF) patients, congestive heart failure (CHF) confers an increased risk of stroke or systemic thromboembolism.
Cannon, Christopher P +7 more
core +1 more source
Group sequential designs for negative binomial outcomes
, 2018 Count data and recurrent events in clinical trials, such as the number of lesions in magnetic resonance imaging in multiple sclerosis, the number of relapses in multiple sclerosis, the number of hospitalizations in heart failure, and the number of ...
Friede, Tim +3 more
core +1 more source
Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial
ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad +9 more
wiley +1 more source
The heavy heart of HFpEF [PDF]
European Heart Journal, 2020 Barry A Borlaug, Joseph J Maleszewski
openaire +2 more sources
iMetaMed, EarlyView.This study analyzed 236 heart failure with preserved ejection fraction (HFpEF) pharmacological trials registered on ClinicalTrials.gov from 2003 to 2025, revealing a post‐2016 surge (76.3%), U.S. dominance (58.5%), and prominence of SGLT2 inhibitors/novel therapies (each 13.1%).
Yucheng Hou +6 more
wiley +1 more source
New in the diagnosis of heart failure and management of associated conditions in 2021 ESC guidelines
Heart Vessels and Transplantation, 2021 Oben Baysan +2 more
doaj +1 more source